Compare UiPath Inc (PATH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Pfizer Inc — how do they compare? UiPath Inc trades at $10.66 (market cap $6.24B), while Pfizer Inc trades at $24.9 (market cap $142.14B). The key difference: Pfizer Inc is far larger — about 22.8× UiPath Inc's market cap, and Pfizer Inc pays a 6.9% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | PFE | |
|---|---|---|
Market Cap | $6.24B | $142.14B |
Sector | Technology | Health |
52-Week High | $19.29 | $28.56 |
52-Week Low | $9.38 | $23.29 |
Enterprise Value | $5.01B | $192.80B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $12.04, down 0.91% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while narrowing net losses signal a path toward sustained profitability. Recent news highlights strong annual recurring revenue growth to $1.9B and strategic AI automation developments through its Maestro platform.
The investment outlook is cautiously optimistic, supported by analyst consensus and improving margins, but risks include competitive pressures in AI automation and volatility in software spending. The stock presents a potential opportunity if execution on profitability continues, though near-term earnings misses warrant monitoring.
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
